Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29494119 | 1.00 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2LMNAHTTCYP1A2 | |
| SCHEMBL8877823 | 0.84 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2LMNAHTTCYP1A2 | |
| SCHEMBL8117537 | 0.81 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2LMNAHTTCYP1A2 | |
| SCHEMBL658520 | 0.81 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2LMNAHTTCYP1A2 | |
| SCHEMBL837194 | 0.81 | HPGD (0.37) | ALDH1A1SMN1; SMN2LMNACYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL8117330 | 0.79 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2LMNAHTTCYP1A2 | |
| SCHEMBL2819365 | 0.78 | — | — | |
| SCHEMBL658720 | 0.78 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2LMNAHTTCYP1A2 | |
| SCHEMBL6987008 | 0.78 | — | — | |
| SCHEMBL29793360 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | claimed |
| CN-104586752-B | A kind of glucose-sensitive self-discipline formula insulin releasing microgel carrier and preparation method thereof | 湖北大学 | 2017-09-01 | — | — | CN | claimed |
| EP-4230219-B1 | PHARMACEUTICAL COMPOSITION COMPRISING GLUCAGON/GLP-1/GIP TRIPLE AGONIST OR LONG-ACTING CONJUGATE THEREOF FOR PREVENTING OR TREATING LUPUS-RELATED DISEASES | HANMI PHARMACEUTICAL CO LTD (KR) | 2026-04-08 | — | — | EP | disclosed |
| US-12552850-B2 | GLP-1/GIP dual agonist, long-acting conjugate thereof, and pharmaceutical composition comprising same | HANMI PHARM. CO., LTD. (KR) | 2026-02-17 | — | — | US | disclosed |
| US-20260022143-A1 | Cyclic Peptide Inhibitors of IL-23 | JANSSEN PHARMACEUTICA NV (BE) | 2026-01-22 | — | — | US | disclosed |
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | TRUSTEES OF TUFTS COLLEGE | 2026-01-08 | — | — | US | disclosed |
| EP-3592761-B1 | NEW ANTIBACTERIAL PRODUCTS | UNIV LIVERPOOL (GB) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025082461-A1 | POLYPEPTIDE, BIOACTIVE CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 优洛生物(上海)有限公司 | 2025-04-24 | — | — | WO | disclosed |
| US-20250026763-A1 | EGFR INHIBITORS AND METHODS OF USE THEREOF | Allorion Therapeutics Inc | 2025-01-23 | — | — | US | disclosed |
| WO-2024256834-A1 | TEIXOBACTINS ANALOGUES AS ANTI-BIOFILM AGENTS | UNIVERSITY OF LIVERPOOL (GB) | 2024-12-19 | — | — | WO | disclosed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
| EP-1614684-A1 | DIAMINE DERIVATIVE, PRODUCTION PROCESS, AND ANTIOXIDIZING DRUG | NIPPON SODA CO., LTD. (JP) | 2006-01-11 | — | — | EP | disclosed |
| US-6867011-B1 | Synthetic bioepitope compounds which can be used as standards in the biological assays of Troponin I | BIO-RAD PASTEUR (FR) | 2005-03-15 | — | — | US | disclosed |
| US-6822074-B1 | COMPRISES CYCLIZATION OF PRECURSOR; FOR IMPROVED YIELD | MERCK PATENT GMBH (DE) | 2004-11-23 | — | — | US | disclosed |
| WO-1999051625-A9 | PEPTIDES CAUSING FORMATION OF COMPACT STRUCTURES | RIGEL PHARMACEUTICALS INC (US) | 2001-07-05 | — | — | WO | disclosed |
| EP-1071705-A2 | PEPTIDES CAUSING FORMATION OF COMPACT STRUCTURES | Rigel Pharmaceuticals, Inc. (US) | 2001-01-31 | — | — | EP | disclosed |
| WO-1999051625-A2 | PEPTIDES CAUSING FORMATION OF COMPACT STRUCTURES | RIGEL PHARMACEUTICALS, INC. (US) | 1999-10-14 | — | — | WO | disclosed |
| CN-1174704-A | Medicinal composition for inhibiting fat peroxide forming | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-03-04 | — | — | CN | disclosed |
| US-5631208-A | Herbicidal cyclohexane-1,3-dione derivatives and their preparation process | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1997-05-20 | — | — | US | disclosed |
| WO-1994003443-A1 | HERBICIDAL CYCLOHEXANE-1,3-DIONE DERIVATIVES AND THEIR PREPARATION PROCESS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1994-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | FIBP, FRS2, FGFR1 | ALDH1A1 2378/4885SMN1; SMN2 4443/4885LMNA 1947/4885 |
| US-20260022143-A1 | Cyclic Peptide Inhibitors of IL-23 | IL23R, IL17A, IL36G | ALDH1A1 4865/4885SMN1; SMN2 2640/4885LMNA 1399/4885 |
| US-12552850-B2 | GLP-1/GIP dual agonist, long-acting conjugate thereof, and pharmaceutical composition comprising same | GLP1R, VIP, GIPR | ALDH1A1 4041/4885SMN1; SMN2 2546/4885LMNA 4432/4885 |
| US-20250026763-A1 | EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB3, ERBB2 | ALDH1A1 4536/4885SMN1; SMN2 4856/4885LMNA 4866/4885 |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | ALDH1A1 4472/4885SMN1; SMN2 4155/4885LMNA 4108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.